Blue Whale Update: Seven Years – Investing Over the Full Market Cycle



 

Stephen Yiu is the Chief Investment Officer at Blue Whale Capital and Lead Manager of the Blue Whale Growth Fund.

Stephen co-founded Blue Whale Capital with Peter Hargreaves, co-founder of Hargreaves Lansdown, in 2016. The Blue Whale Growth Fund was launched in September 2020 and is a long-only global equity fund focusing on developed markets.

Stephen adopts a high conviction, active approach based on
bottom-up, fundamental research.

Much is made about past performance of investments. The compliance adage “past performance is not a guide to the future” is a fair one. And for good reason – what is in the past cannot be attained. Sadly, past performance really is the only graphical metric that most people look at when choosing their investment.

This doesn’t upset us – indeed it reflects well on the Blue Whale Growth Strategy – we have delivered performance of +129% over our seven years for our investors*.

However, what should really interest investors is the story moving forward. How is the portfolio positioned to take advantage of opportunities, but defend against pitfalls? Is there strong idea generation? It is, after all, what happens in the future that decides returns from here.

Looking back

Seven years is a strange metric, but we feel it’s an important one. We could consider the last seven years as being representative of a full market cycle – the steady growth of 2018 and 2019, the bust and boom of pandemic year 2020, the consolidation of a “new world” in 2021, the fallout from high consumption and low productivity hitting in 2022, monetary policy leading to rapidly rising interest rates in an inflationary environment, and energy cost rises compounding a difficult macro outlook, and then steadying interest rates as Western governments attempt to head off recession in 2024.

All these events played out against a backdrop of political upheaval with lacklustre politicians leading to chops and changes at home and abroad. Geopolitics have also been highly unsettled with war in Ukraine and the Middle East, and China threatening to expand its influence in the South China Sea.

I think we can all agree, uncertainty has been the order of the day for the last seven years. And if there is anything markets hate, it is uncertainty.

Yet, the Blue Whale Growth Strategy has transcended these issues to comfortably more than double early investor’s money. The nature of the Strategy, being a high conviction portfolio of only 25-30 stocks and our refusal to rotate into poor quality companies, means that short term volatility has of course been present, but given the major events around the world over this time, this is not surprising.

Into the future

Contentious presidential elections in the US, fractured and polarised parties on the Continent, and a new regime in the UK already making a series of tone-deaf missteps – both at home and abroad the political landscape looks shaky at best. Sadly, the geopolitical tensions noted above remain troubling. Monetary policy across Western economies continues to be a concern, as central banks try to balance the need to curb inflation, whilst not tipping their respective economies into recession.

Nevertheless, despite these potential macro headwinds, we see geopolitics and political wrangling as risk factors that would likely affect poorer quality businesses. We have built a portfolio of companies that we believe should transcend these issues, all the while taking advantage of global mega trends to drive outsized returns for investors. We wrote about this in a recent article you can read here. Possibly link to previous article “Transcendent Companies”

What do they think we are?

In the early days, we were regularly “accused” of being a technology play. This used to annoy me. But having had time to reflect on this label, I am actually quite proud.

With a global growth mandate, we were able to invest in any sector we wished, but we did hold, on average, around 40% of our assets in “tech” stocks as we saw these companies offering the best opportunity for outperformance. “Your performance is only good because you’re invested in tech”. The label shouldn’t have bothered me. It simply suggested we were invested in the right stocks at the time.

In future, if we are labelled an AI fund, healthcare fund, or industrials fund, I will embrace it – providing the particular sectors in which we are majority invested perform as well as “tech” did for us in our early days!

What we actually are

If you were to ask me today, I wouldn’t label the Strategy as any of these things. What we are is your one-stop shop for navigating the markets. It is a strategy that aims to compound returns, with the sole intention of delivering consistent outperformance of the index.

We can invest where we like. That usually means a quality business benefitting from the tailwinds of sector growth. We did it with Alphabet and digital advertising, Microsoft and digital transformation, Nvidia and AI. We are already looking for the next great companies, in the next exciting sectors. We believe we have already found them.

So, if you are going to consider the past, judge a manager through a cycle, through good times and bad, high interest rates, low interest rates, crises etc. Can they outperform under these circumstances? If you look back, you will see that we have.

But if you want to look to the future, which is where any further gains will come going forward, then you need to understand how we invest, and, more importantly, why we invest. The “why” is as follows – we invest to compound returns, with the sole intention of delivering outperformance of the index for our investors. The way we invest, as ever, is to run a concentrated portfolio of high-quality businesses, conducting our own research across a broad range of sectors and geographies. As noted above, investors need to be aware that past performance is not a guide to the future, and you need to be prepared to ride out volatility, but we believe this formula gives us the best chance of outperforming our peers. The last seven years have proved us right so far.

Our performance has been good, but I want it to be even better over the next cycle. Are there challenges ahead? Doubtless. But you can rest assured that the team and I relish such challenges, and we aim to rise to the occasion. Here’s to the next seven years and beyond.

*Simulated performance of WS Blue Whale Growth Fund, I class Acc shares, net of fees priced at midday UK time for the period 11/09/2017 to 25/09/2020 and Blue Whale Growth Fund T-Acc (GBP), net of fees priced at midday UK time for the period 25/09/2020 to 30/09/2024, source: Bloomberg.

Please note that references to the LF Blue Whale Growth Fund in the article are provided for information purposes only; it is a UK UCITS which is not registered for sale in, nor promoted, to investors in the EEA. The Blue Whale Investment Funds ICAV Blue Whale Growth Fund was launched in September 2020 and is available to MeDirect clients. Whilst the investment objectives and charges are not identical, both funds are run on the same investment process.

Blue Whale Growth Fund is manufactured by Blue Whale Capital LLP and represented in Malta by MeDirect Bank (Malta) plc.

 


Blue Whale Key Risks & Disclaimers:

The Blue Whale Growth Fund was launched in September 2020. All references to actions before this date relate to the LF Blue Whale Growth Fund.  Information on the LF Blue Whale Growth Fund is provided for comparison purposes only; it is a UK UCITS which is not registered for sale in nor is it promoted to investors in the EEA.  Whilst the investment objectives and charges are not identical, both funds are run on the same investment process.

Please note that the information provided in this article is not to be construed as advice and any views we express on holdings do not constitute investment recommendations and must not be viewed as such. If you are unsure as to the suitability of an investment for your circumstances, please seek independent financial advice. Investments can go down in value as well as up so you may get back less than you invested. Your capital is at risk. Past performance is not a guide to future performance.Blue Whale Capital LLP is authorised and regulated by the UK Financial Conduct Authority.

There are significant risks associated with investment in the Fund referred to herein. Investment in the Fund is intended for investors who understand and can accept the risks associated with such an investment including potentially a substantial or complete loss of their investment.

Past performance is not a guide to future performance. The value of investments and any income derived from them can go down as well as up and the value of your investment may be volatile and be subject to sudden and substantial falls.

Investment in a Fund with exposure to emerging markets involves risk factors and special considerations which may not be typically associated with investing in more developed markets. Political or economic change and instability may be more likely to occur and have a greater effect on the economies and markets of emerging countries. Adverse government policies, taxation, restrictions on foreign investment and on currency convertibility and repatriation, currency fluctuations and other developments in the laws and regulations of emerging countries in which investment may be made, including expropriation, nationalisation or other confiscation could result in loss to the Fund.

Income from investments may fluctuate. Changes in rates of exchange may have an adverse effect on the value, price or income of investments. Fund charges may be applied in whole or part to capital, which may result in capital erosion. The Authorised Corporate Director may apply a dilution adjustment as detailed in the Prospectus. The Fund is not traded on an exchange or recognised market.

The foregoing list of risk factors is not complete, and reference should be made to the Fund’s Prospectus, KIID and application form.


MeDirect Disclaimers:

This information has been accurately reproduced, as received from Blue Whale Growth Fund. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document are intended for retail clients, however, it may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. The performance figures quoted are only estimates and may not be a reliable indicator of future performance of this investment. Any decision to invest in a mutual fund should always be based upon the details contained in the Prospectus and Key Information Document (KID), which may be obtained from MeDirect Bank (Malta) plc.

BlackRock Commentary: Our conviction in global stocks

Wei Li – Global Chief Investment Strategist of BlackRock Investment Institute together with Roelof Salomons – Chief Investment Strategist for the Netherlands, Ben Powell – Chief Investment Strategist for the Middle East and APAC and Devan Nathwani – Portfolio Strategist all forming part of the BlackRock Investment Institute share their insights on global economy, markets and geopolitics. Their views are theirs alone and are not intended to be construed as investment advice.

Key Points

Going global: We see opportunities in global stocks trading at attractive relative valuations with potential catalysts for price appreciation – like in China and Japan.

Market backdrop: U.S. stocks hit all-time highs. U.S. 10-year yields rose further after the U.S. core CPI data prompted markets to trim expectations for Federal Reserve rate cuts.

Week ahead: This week, we expect the European Central Bank to cut interest rates. We think it has more room to cut rates than the Fed because it tightened policy more. 

China’s share surge shows the upside of keying on opportunities in global stocks when clear catalysts emerge. We keep our U.S. equity overweight on the artificial intelligence (AI) theme broadening. Outside the U.S., we favor markets where we have high conviction. We’re overweight Japanese stocks on a solid macro outlook and corporate reforms. We stay overweight UK stocks with less conviction. We upgrade UK gilts and see room for sharper policy rate cuts than markets expect.

China is the latest example of how cheap valuations can turn into a stock market rally once a catalyst emerges. Chinese shares have surged since the September politburo meeting on hopes that major fiscal stimulus may be on the way. A lack of details so far has disappointed some investors, so we eye policy announcements for more clarity. This potential exists elsewhere, waiting for a catalyst to give a spark, we think. But selectivity is key. We see a widening gap in economic performance and equity valuations across regions – a function of a more volatile macro backdrop and uneven restart coming out of the pandemic. See the chart. We still like U.S. stocks and the broad AI theme as corporate earnings growth expands beyond tech. Yet fears over stretched valuations can drive brief selloffs. This calls for considering global exposure where we see cheap valuations and potential catalysts.

Staying nimble allows us to seize on opportunities in global equities when catalysts emerge. China’s signal on policy stimulus prompted us to go modestly overweight, especially given depressed valuations. Details have been scant, so we could change our view if future announcements disappoint. We still think China faces long-term, structural challenges – like economic and geopolitical competition with the West, government debt and population aging. We have stayed overweight Japan stocks on a sunnier macro backdrop and corporate reforms driving strong earnings and shareholder returns. We trimmed our overweight in August due to the potential drag on earnings from a stronger yen and Bank of Japan policy missteps – yet we stay positive.

How we’re staying selective

Even in regions where the growth outlook is more challenging, we see selective investment opportunities. With 11% gains this year, European stocks have lagged major markets – yet European banks have surged 31% and we still like the sector as we have since the start of 2024. We have less conviction in UK stocks on a soft economy and heading into the new government’s budget announcement, yet we stay overweight for now. We go overweight UK gilts as we see the Bank of England having to cut policy rates more than markets are pricing given the soft economy.

We lean into risk yet monitor signposts that could cause us to change our views. Geopolitical risk is elevated as tensions flare in the Middle East. Regional escalation could drive oil prices higher, highlighting this is a world shaped by supply constraints. We have seen oil price spikes drive bond yields higher, showing long-term bonds still aren’t providing reliable portfolio diversification, in our view. This makes quality key in fixed income, we think. The U.S. election will have global ramifications, especially for key trade partners like Mexico. Yet mega forces, structural shifts impacting returns now and in the future, are driving opportunities beyond the near-term risks. For example, the rewiring of supply chains is benefiting multi-aligned trading partners like Vietnam and Indonesia, both seeing a significant increase in trade and investment flows.

Our bottom line

We stay nimble to seize high-conviction global opportunities. We recently turned modestly overweight Chinese equities and stay overweight Japanese and UK equities. We up UK gilts to overweight and stay cautious on U.S. Treasuries.

Market backdrop

U.S. stocks hit all-time highs, with tech shares leading gains, as the Q3 earnings season kicked off. U.S. 10-year Treasury yields climbed further to their highest since July near 4.10%, up about 50 basis points in the past month. U.S. core inflation topped expectations in September, showing sticky services inflation and leading markets to trim expected Federal Reserve rate cuts. China onshore shares fell 3% last week, forfeiting some recent gains as investors eye fiscal stimulus details.

We expect the European Central Bank (ECB) to cut interest rates at its policy meeting this week. September core inflation was below ECB projections, indicating inflation is still on track to hit the central bank’s 2% target. We think the euro area’s substantially weaker growth and employment indicators will push the ECB to cut rates again in October. The ECB will likely remain focused on incoming data but it has more room to cut than the Fed because it tightened policy more, in our view.

Week Ahead

Oct. 14: China trade data

Oct. 15: UK employment data

Oct. 16: UK CPI

Oct. 17: ECB policy decision; Philly Fed business index; Japan trade data


BlackRock’s Key risks & Disclaimers:

This material is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of 14th October, 2024 and may change. The information and opinions are derived from proprietary and non-proprietary sources deemed by BlackRock to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by BlackRock, its officers, employees or agents. This material may contain ’forward looking’ information that is not purely historical in nature. Such information may include, among other things, projections and forecasts. There is no guarantee that any forecasts made will come to pass. Reliance upon information in this material is at the sole discretion of the reader.

The information provided here is neither tax nor legal advice. Investors should speak to their tax professional for specific information regarding their tax situation. Investment involves risk including possible loss of principal. International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation, and the possibility of substantial volatility due to adverse political, economic or other developments. These risks are often heightened for investments in emerging/developing markets or smaller capital markets.

Issued by BlackRock Investment Management (UK) Limited, authorized and regulated by the Financial Conduct Authority. Registered office: 12 Throgmorton Avenue, London, EC2N 2DL.


MeDirect Disclaimers:

This information has been accurately reproduced, as received from  BlackRock Investment Management (UK) Limited. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document is intended for retail clients however, it may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest in a mutual fund should always be based upon the details contained in the Prospectus and Key Information Document (KID), which may be obtained from MeDirect Bank (Malta) plc.

You are leaving medirect.com.mt

Please be aware that the external site policies, or those of another MeDirect website, may differ from this website’s terms and conditions and privacy policy. The next website will open in a new browser window or tab.

 

Note: MeDirect is not responsible for any content on third party sites, nor does a link suggest endorsement of those sites and/or their content.

Login

We strive to ensure a streamlined account opening process, via a structured and clear set of requirements and personalised assistance during the initial communication stages. If you are interested in opening a corporate account with MeDirect, please complete an Account Opening Information Questionnaire and send it to corporate@medirect.com.mt.

For a comprehensive list of documentation required to open a corporate account please contact us by email at corporate@medirect.com.mt or by phone on (+356) 2557 4444.